PROM1 and carcinoma: Interestingly, we found that carcinoma patients with higher renal CD133/CYP1B1 expression had better outcomes compared to those with lower CD133/CYP1B1 expression (p = 0.05 and p = 6 × 10−4, respectively; Figure 7A,B).